144 related articles for article (PubMed ID: 35416922)
1. ABO blood group type and risk of venous thromboembolism in patients with cancer.
Englisch C; Moik F; Nopp S; Raderer M; Pabinger I; Ay C
Blood Adv; 2022 Dec; 6(24):6274-6281. PubMed ID: 35416922
[TBL] [Abstract][Full Text] [Related]
2. B blood group: A strong risk factor for venous thromboembolism recurrence.
Baudouy D; Moceri P; Chiche O; Bouvier P; Schouver ED; Cerboni P; Gibelin P; Ferrari E
Thromb Res; 2015 Jul; 136(1):107-11. PubMed ID: 25981188
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.
Englisch C; Moik F; Thaler J; Koder S; Mackman N; Preusser M; Pabinger I; Ay C
Haematologica; 2024 Apr; 109(4):1128-1136. PubMed ID: 37822244
[TBL] [Abstract][Full Text] [Related]
4. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).
Ohira T; Cushman M; Tsai MY; Zhang Y; Heckbert SR; Zakai NA; Rosamond WD; Folsom AR
J Thromb Haemost; 2007 Jul; 5(7):1455-61. PubMed ID: 17425663
[TBL] [Abstract][Full Text] [Related]
5. The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex.
Shusterman M; Golub E; Mowrey WB; Broder A
Lupus; 2018 Feb; 27(2):319-326. PubMed ID: 28705035
[TBL] [Abstract][Full Text] [Related]
6. ABO blood types associated with the risk of venous thromboembolism in Han Chinese people: A hospital-based study of 200,000 patients.
Sun X; Feng J; Wu W; Peng M; Shi J
Sci Rep; 2017 Mar; 7():42925. PubMed ID: 28262729
[TBL] [Abstract][Full Text] [Related]
7. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature.
Dentali F; Sironi AP; Ageno W; Turato S; Bonfanti C; Frattini F; Crestani S; Franchini M
Semin Thromb Hemost; 2012 Jul; 38(5):535-48. PubMed ID: 22740183
[TBL] [Abstract][Full Text] [Related]
8. Association between smoking and recurrence of venous thromboembolism and bleeding in elderly patients with past acute venous thromboembolism.
Carruzzo P; Méan M; Limacher A; Aujesky D; Cornuz J; Clair C
Thromb Res; 2016 Feb; 138():74-79. PubMed ID: 26688323
[TBL] [Abstract][Full Text] [Related]
9. Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Posch F; Thaler J; Zlabinger GJ; Königsbrügge O; Koder S; Zielinski C; Pabinger I; Ay C
Clin Cancer Res; 2016 Jan; 22(1):200-6. PubMed ID: 26302981
[TBL] [Abstract][Full Text] [Related]
10. Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy.
Bhanvadia S; Kazerouni K; Bazargani ST; Miranda G; Cai J; Daneshmand S; Djaladat H
World J Urol; 2019 Jan; 37(1):173-179. PubMed ID: 29876671
[TBL] [Abstract][Full Text] [Related]
11. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Khorana AA; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Lee AY
J Clin Oncol; 2017 Apr; 35(10):1078-1085. PubMed ID: 28029329
[TBL] [Abstract][Full Text] [Related]
12. ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review.
Elsherif S; Zidan A; Saville O; Othman M
Semin Thromb Hemost; 2024 Apr; 50(3):423-428. PubMed ID: 37751774
[TBL] [Abstract][Full Text] [Related]
13. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality.
Riedl J; Posch F; Königsbrügge O; Lötsch F; Reitter EM; Eigenbauer E; Marosi C; Schwarzinger I; Zielinski C; Pabinger I; Ay C
PLoS One; 2014; 9(10):e111440. PubMed ID: 25347577
[TBL] [Abstract][Full Text] [Related]
14. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors.
Streiff MB; Ye X; Kickler TS; Desideri S; Jani J; Fisher J; Grossman SA
J Neurooncol; 2015 Sep; 124(2):299-305. PubMed ID: 26100546
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
[TBL] [Abstract][Full Text] [Related]
17. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas.
Streiff MB; Segal J; Grossman SA; Kickler TS; Weir EG
Cancer; 2004 Apr; 100(8):1717-23. PubMed ID: 15073862
[TBL] [Abstract][Full Text] [Related]
18. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
Königsbrügge O; Posch F; Riedl J; Reitter EM; Zielinski C; Pabinger I; Ay C
Oncologist; 2016 Feb; 21(2):252-7. PubMed ID: 26764252
[TBL] [Abstract][Full Text] [Related]
19. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ahlbrecht J; Dickmann B; Ay C; Dunkler D; Thaler J; Schmidinger M; Quehenberger P; Haitel A; Zielinski C; Pabinger I
J Clin Oncol; 2012 Nov; 30(31):3870-5. PubMed ID: 23008313
[TBL] [Abstract][Full Text] [Related]
20. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer.
Giustozzi M; Curcio A; Weijs B; Field TS; Sudikas S; Katholing A; Wallenhorst C; Weitz JI; Martinez C; Cohen AT
Thromb Haemost; 2020 May; 120(5):847-856. PubMed ID: 32369855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
